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OBJECTIVES: Anaemia is a frequent adverse event associated
with chemotherapy. In the past two decades, erythropoiesis-
stimulating drugs have completely changed the treatment and
prevention of chemotherapy-associated anaemia. However, these
drugs have a high unitary cost, meaning that evaluation of their
cost-effectiveness is of great importance. Cost analysis of
erythropoiesis-stimulating drugs implies a comparison with
the cost of a blood transfusion. This study attempts to estimate
the cost of blood in a comprehensive «vein-to-vein» approach,
calculating the cost of a blood transfusion carried out at the
Immunohemotherapy Service of Instituto Português de Oncolo-
gia in Lisbon as treatment for neoplasia-associated anaemia.
METHODS: Cross sectional study, which evaluated the re-
sources and direct costs, associated with a blood transfusion of
two red blood cells units in patients with hemato-oncologic
disease. Hospital and National Health System perspectives were
applied. Data regarding consumables, human resources, labora-
tory analysis and occupation of facilities was collected by direct
observation for a period of seven consecutive days. Data was
collected for blood donation, blood-screening analysis and trans-
fusion itself, at the Instituto Português de Oncologia. Costs for
each item were given by the Instituto Português de Oncologia.
RESULTS: The estimated cost of two red blood cells units trans-
fusion was €676.20, the greatest proportion of which was
attributed to blood preparation, analysis and storage. CONCLU-
SIONS: Determining the actual costs in relation to standard
medical actions and procedures is essential for a robust analysis
of the cost-effectiveness of new drugs. This study evaluated all
the costs involved in transfusing two red blood cells units and the
results presented are consistent with those obtained by several
other authors in European countries.
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OBJECTIVES: Trauma, surgery, and abnormalities in hemosta-
sis are common causes of excessive bleeding and the need for
blood transfusion. Factors such as acute shortages in blood
inventory, rising costs of blood products, and inherent risks
associated with blood transfusion increasingly warrant limiting
the inappropriate use of blood and broader adoption of blood
conservation techniques and strategies. The aim of this study
was to estimate morbidity, mortality, and resource-use associ-
ated with blood transfusion in hospitalized patients in the U.S.
in 2004. METHODS: The 2004 Healthcare Cost and Utiliza-
tion Project Nationwide Inpatient Sample was queried to group
discharges into Transfused and Non-Transfused cohorts based
on International Classiﬁcation of Diseases, Ninth Revision,
Clinical Modiﬁcation procedure codes for blood transfusion.
Average differences between cohorts in length of stay (LOS)
and total hospital charges were calculated. Odds ratios were
calculated for mortality and postoperative infection rates.
Results are reported after controlling for age, gender, co-
morbidities, admission type, and diagnosis related group.
RESULTS: LOS, charges, mortality, and infection were signiﬁ-
cantly higher in transfused patients than in non-transfused
patients. The average difference in LOS was 3.0 days higher
among the Transfused cohort (p < 0.0001; F test) and average
difference in charges were $8476 higher for the Transfused
cohort (p < 0.0001; F test) compared to the Non-Transfused
cohort. Additionally, the Transfused cohort had a 1.6 times
higher odds of death (p < 0.0001; Rao-Scott chi-square test)
and a 2.3 times higher odds of infection (p < 0.0001; Rao-Scott
chi-square test) compared to the Non-Transfused cohort. CON-
CLUSIONS: Our study demonstrates that hospitalized patients
receiving blood transfusions remain at risk for experiencing
adverse clinical and economic outcomes. Raising awareness
about the potential negative clinical and economic outcomes of
blood transfusion may encourage the adoption of blood con-
servation techniques and strategies, reduce the need for trans-
fusions, and ultimately, yield meaningful clinical beneﬁts at the
individual patient level.
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OBJECTIVES: To evaluate costs related to health care resource
use and PRO in German patients with chronic knee and/or
hip pain, speciﬁcally for guideline-, non-guideline- and self-
treatment-groups. METHODS: Patients (n = 126) were con-
secutively recruited by physicians in general practice (n = 49) in
2005 and categorized into the three groups (n = 61 self-treatment,
n = 19 guideline-, n = 46 non-guideline-groups). PRO were
assessed by SF-36, von Korff Index, and Patient Health Question-
naire Depression (PHQ-D) questionnaires at time of enrollment.
Resource utilization data was collected retrospectively for six
months. Groups were compared using multivariate general linear
modeling (GLM). RESULTS: Participants had an average dura-
tion of knee and/or hip pain of about 5.4 years, were on average 60
years old, predominantly females (71%), overweight (mean BMI
27.8 kg/m2) and unemployed (69%). Patients with self-treatment
were younger compared to guideline- or non-guideline patients
(54.4 vs. 63.7 vs. 65.5 years, mean age, p = 0.0070). Regarding
SF-36, von Korff Index, and PHQ-D (with exception of major
depressive symptoms) the groups were similar.Mean total societal
perspective costs per patient were €210.22 [95%CI 77.47;
342.97] vs. €2886.07 [95%CI 107.93; 5664.21] vs. €1087.50
[95%CI 600.73; 1574.27] (self-treatment-vs. guideline-vs. non-
guideline-group, respectively, p = 0.0686, adjusted by age and
employment status). The major cost factors were: in the self-
treatment-group, hospitalizations, remedies, and sport activities
(29.3%, 27.9%, and 21.9% of the mean total cost per patient,
respectively); in the guideline-group, hospitalizations, sick leaves,
and remedies (25.8%, 24.6%, and 19.6%, respectively); and for
the non-guideline-group, remedies, hospitalizations, and visits to
physicians (19.8%, 19.0%, and 13.7%, respectively). CONCLU-
SIONS: PRO in patients with chronic knee and/or hip pain are
worse compared to the general reference population in Germany.
However, PRO and societal mean total adjusted costs per patient
with knee and/or hip pain are comparable among guideline-,
non-guideline- and self-treatment-groups.
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